Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Division of Neurosurgery, Shizuoka Cancer Center Hospital, Shizuoka, Japan.
Anticancer Res. 2020 Nov;40(11):6473-6484. doi: 10.21873/anticanres.14669.
BACKGROUND/AIM: Glioblastoma multiforme (GBM) is an intractable tumor that has a very poor prognosis despite intensive treatment with temozolomide plus radiotherapy.
Sixteen newly diagnosed patients with high-grade gliomas were enrolled in a phase II study of the α-type-1 DC vaccine. Briefly, DCs obtained from the culture of enriched monocytes in the presence of a cytokine cocktail, were pulsed with a cocktail of 5 synthetic peptides and cryopreserved until injection into patients.
The amount of IL-12 produced by activated DCs was higher than that previously reported. Among 15 evaluable patients, 10 showed positive CTL responses to any peptides in an ELISPOT assay. After 6 years of observation, five patients were still alive, and two of these patients were relapse-free. Moreover, a significant survival-prolonging effect was verified in DC-treated glioma patients.
Peptide-cocktail-pulsed α-type-1 DC vaccines have a potential therapeutic effect on survival when used in combination with the standard regimen, which is partly based on IL-12-IFN-γ-mediated T-cell activation.
背景/目的：尽管采用替莫唑胺联合放疗进行强化治疗，胶质母细胞瘤（GBM）仍是一种难以治疗的肿瘤，预后极差。
16 例新诊断的高级别胶质瘤患者入组了α-1 型 DC 疫苗的 II 期研究。简要来说，在细胞因子鸡尾酒存在的情况下，从富集的单核细胞培养物中获得的 DC 被 5 种合成肽鸡尾酒脉冲处理，并冷冻保存，直到注射给患者。
激活的 DC 产生的 IL-12 量高于以前报道的水平。在 15 例可评估的患者中，10 例在 ELISPOT 检测中对任何肽均显示出阳性 CTL 反应。经过 6 年的观察，5 例患者仍然存活，其中 2 例无复发。此外，在接受 DC 治疗的脑肿瘤患者中，观察到了显著的生存延长效果。
与标准方案联合使用时，肽鸡尾酒脉冲 α-1 型 DC 疫苗具有潜在的治疗效果，这部分是基于 IL-12-IFN-γ 介导的 T 细胞激活。
